Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1521P - Polypharmacy and therapeutic futility in patients near the end of life


17 Sep 2020


E-Poster Display


End-of-Life Care

Tumour Site


Joana Graca


Annals of Oncology (2020) 31 (suppl_4): S874-S880. 10.1016/annonc/annonc264


J.A. Graca, A.L.V. Matos, J. Barata, L. Fernandes, M.M. Pinto, A. Martins

Author affiliations

  • Medical Oncology Department, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), 1449-005 - Lisbon/PT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1521P


The goal for end-of-life cancer patients should be symptom control and improving quality of life through therapeutic optimization and discontinuing futile therapy. However, the maintenance of unneeded drugs is frequent, increasing the risk of harmful drug interactions. The aim of this study was to quantify the number of patients with advanced cancer receiving unnecessary therapies and identify points for improvement in clinical practice.


This was a retrospective and observational single-centre study, which included cancer patients that died in the medical oncology unit during a 24 month period. A prognostic score (PaP score) was applied retrospectively. The last chemotherapy (ChT) treatment and drugs prescribed at admission and 24 hours prior to death were analysed and were potentially inappropriate medications (PIMs) were identified.


Seventy-four patients were included in the study. On day 1, 89.2% were exposed to at least one PIM, mainly cardiovascular drugs (28.4%), anticoagulants (43.2%), and proton pump inhibitors (74.3%). Twenty-seven patients (36.5%) had a PaP score > 11 (30 day survival probability < 30%). However, there was no significant difference in terms of PIMS in the group with a PaP score > 11 compared to the overall cohort. Therapeutic simplification occurred in 27 patients (36.5%), but PIMs were maintained in 70.3% of patients. Regarding ChT, 34% of patients had ChT in the last two months of life, and 8% in the last two weeks.


The prevalence of polypharmacy and PIMs in advanced cancer patients is high. There is a clear need to perform regular prognostic assessments and apply validated prognostic scores to improve clinical practice. Prescriptions must be assessed continuously, aiming to reduce inappropriate drugs, including discontinuation of oncospecific therapy, and favouring symptomatic control and quality of life.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.